한국지질동맥경화학회 학술대회

Gut microbiota remodeling in infection and inflammation

Intermittent fasting as a nutritional intervention to modulate macrophage polarization for vascular health

Spatiotemporal immune activation drives metabolic quiescence in brown adipose tissue

LDL versus inflammation: what remains after aggressive lipid lowering?

Emerging anti-inflammatory therapies in ASCVD: canakinumab, NLRP3 inhibitors, and beyond

Colchicine for secondary prevention in ASCVD

Immune mechanisms of residual cardiovascular risk: from oxidation-specific epitopes to therapeutic targets

Biobank resources for human metabolic and vascular research

Leveraging biobank platforms to study cardiometabolic physiology and disease

Integrative analysis of metabolic dysfunction

Refined risk assessment in FH

Cause of death in FH

Experience on new drugs for FH: including lomitapide & evinacumab

Genome editing for precision medicine

The race to the bottom: intensive LDL-C lowering in very high-risk Asian patients

Combination therapy in high-risk patients: early vs stepwise approach

Practical approaches to statin intolerance: from clinical trials to real-world solutions

GLP1 RA for stroke prevention

SGLT2 inhibitor for stroke survivors

GLP-1 receptor agonists in Alzheimer’s disease

Choosing the right combination therapy: statin, ezetimibe, PCSK9 inhibitor, or beyond?

Korean Fact Sheet: Current status of LDL-C control and cardiovascular risk

Korean Fact Sheet: Real-world utilization of lipid lowering agents

Why are LDL-C targets still unmet? common errors and practical solutions in the clinic

Do East Asians need lower statin intensity? ethnic differences in LDL-C response and safety

Why TG is important in Asians?

Genetic stratification and treatment response in Korean severe hypertriglyceridemia: a prospective multicenter registry study

Chylomicronemia: past, present and future

Sex differences in lymphatic function and atherosclerosis outcomes

Tirzepatide and cardiometabolic outcomes: implications of dual GLP-1/GIP agonism

Effects of SGLT2 inhibitors on lipid metabolism: mechanisms and clinical implications

Lipid abnormalities in CKD

Why patients with CKD develop accelerated atherosclerosis

Cardiovascular prevention in CKD patients

Evolving LDL-C management: guidelines and the role of evolocumab

TBD (Lecture Title)

Bridging guidelines and practice: strategic implementation of combination therapy in lipid management

Paving the road for optimal LDL-C management: new evidence on intensive LDL-C targeting from the Ez-PAVE trial

The role of DPP-4 inhibitors in Korean diabetes care: focusing on K-evidence

The smaller the better: rovazet

Bempedoic acid: LDL-C lowering beyond statins - evidence and clinical role

Optimizing non-statin therapy: PCSK9 inhibitors and inclisiran

Emerging Lp(a)-lowering therapies: siRNA, ASO, and beyond

Lipid-lowering therapy in people living with HIV (PLWH)

Lipid-lowering therapy in cancer patients and survivors

Lipid-lowering therapy in patients with CKD

Cardiovascular prevention in hemodialysis: is omega-3 back?

Ion channels in atherosclerosis: from calcium flux to vascular dysfunction

Energy metabolism and lipid oxidation in cardiometabolic pathophysiology

Lp(a), oxidized phospholipids, and atherosclerosis

Lipoprotein(a): the next frontier in cardiovascular prevention

Medicine in art (그림 속의 의학)

Evolving lipid management: early combination & the CKM paradigm

Beyond the statin, ROSUZET; start early, switch now

Be the standard ROSUZET; evidence-driven lipid management

TBD (Lecture Title)

TBD (Lecture Title)

Clinical updates in dyslipidemia: positioning baroezet for optimal patient care

Sex differences in lipid profiles and residual cardiovascular risk

Early-onset dyslipidemia in young adults: screening strategies and lifetime ASCVD risk assessment

Menopause and cardiometabolic transition: optimizing lipid management in midlife women

The quiet signal, no longer - triglyceride at the crossroads of insulin resistance and cardiometabolic risk

Reliability of lipid-related content on Korean health YouTube

Korean epidemiology and risk modifiers for establishing LDL-C goal strategies

Practical algorithm for intensive lipid lowering therapy in the 2026 Korean guidelines

Nutritional management and lifestyle modification tailored to the Korean dietary pattern

Optimized lipid management for special populations

Lipoprotein(a) in Korean patients: real-world data, cardiovascular risk, and clinical implications

Lipoprotein(a) and coronary atherosclerosis in Vietnam: real-world data and emerging cardiovascular risk

Measuring Lipoprotein(a) in clinical practice: assay challenges, standardization, and interpretation

Evolution of vulnerable plaques: from natural history to preventive intervention

High-risk plaque features on CCTA: identification and clinical implications

Intravascular imaging of vulnerable plaques: insights from IVUS and OCT

Coronary physiology and plaque vulnerability: integrative relationship and prognostic implications

Fatty liver and residual cardiovascular risk: epidemiology and clinical implications

From lipotoxicity to atherosclerosis: MASLD/MetALD subtypes and cardiovascular risk

Therapeutic strategies for cardiometabolic risk reduction in MASLD

Closing the gap between guidelines and reality in dyslipidemia management

PCSK9 inhibition in primary prevention: insights from VESALIUS-CV and clinical implications

Low LDL-C and brain safety: risk of hemorrhagic stroke and cognitive dysfunction

Early combination therapy in primary prevention

CETP inhibition revisited: obicetrapib for LDL-C reduction and ASCVD risk management

APOC3 inhibition: targeting triglyceride-rich lipoproteins and residual risk

ANGPTL3 inhibition: expanding therapeutic opportunities beyond LDL-C

Defining residual cardiovascular risk in the post-LDL era: unmet needs and mechanisms

Targeting residual risk: Lp(a), triglyceride-rich lipoproteins, and inflammation

Residual cardiovascular risk beyond LDL-C: the central role of ApoB lipoproteins

Beyond less is more: navigating residual thrombotic and inflammatory risk in AF and stable CAD

Lipid remodeling of adipose tissue: the hidden link between obesity and atherosclerosis

Remnant cholesterol and residual cardiovascular risk in obesity

Dual targeting of lipid and weight: emerging therapies and clinical strategies

Statin therapy Strategies for Newly Diagnosed Dyslipidemia Patients in Clinical Practice

Low-dose atorvastatin: addressing an unmet clinical need

The role of low-dose fenofibrate in the management of dyslipidemia

A new oral LDL-C lowering agent with proven CV benefit: bempedoic acid

Integrated lipid management across the CKM spectrum: from evidence to practice

TBD (Lecture Title)

TBD (Lecture Title)

The emerging role of ApoB and triglyceride-rich lipoproteins

Beyond LDL-C: targeting inflammation and lipoprotein(a) to address residual cardiovascular risk in Asia

Cardiometabolic residual risk in Asia: diabetes, metabolic dysfunction, and vascular aging

Oxidized phospholipids on lipoprotein(a): a key driver of atherothrombosis?

Does lipoprotein(a) promote thrombosis? evidence from genetics and population studies

Epidemiology and cardiovascular events: what have we learned?

Dyslipidemia across ethnicities in Malaysia: who is at risk, and who is being left behind?

Genetic architecture of dyslipidemia and cardiovascular risk in East Asians: from monogenic variants to polygenic risk

Epidemiological trends of dyslipidemia in Korea and their implications for Asian populations

Beyond LDL-C lowering: strategies for maximizing residual ASCVD risk reduction

Perspective on residual risk, inflammation, and atherosclerosis: from epidemiology to precision prevention

TBD (Lecture Title)

New paradigm of initial therapy for hypertension: which patients benefit from amoprel?

Combination treatment in hypertension: why is losartan-based therapy effective?

TBD (Lecture Title)

Residual cardiovascular risk in hypertension despite optimal BP control

Lipid management in hypertensive patients

Obesity, insulin resistance, and hypertension-related vascular injury

Impact of lipid-lowering therapy on plaque stabilization and regression

Coronary microvascular dysfunction after PCI

Discordance between CAC and coronary stenosis

Hypertriglyceridemia and remnant cholesterol in diabetes

Arterial stiffness and vascular aging in diabetes

Coronary artery calcium and subclinical atherosclerosis in diabetes

Cardiologist perspective: implementing novel cardiometabolic therapies in CVD

Nephrologist’s perspective: kidney protection strategies to improve cardio-kidney outcomes

Endocrinologist perspective: optimizing combination therapy in complex CKM patients

AI-CVD: opportunistic testing of coronary calcium and beyond

From physics to physiology: computational hemodynamics and coronary flow modeling in atherosclerosis

Application of AI to coronary angiography

AI-based retinomics: cardiovascular risk prediction using retinal imaging

Lipid management in primary prevention: who, when, and how aggressive?

Life’s essential 8: concept, evidence, and clinical impact

Advancing cardiovascular management through vaccination

Diabetic dyslipidemia: targeting residual risk beyond LDL-C lowering

Subclinical thyroid dysfunction: when should we treat for lipid control?

Atherogenic dyslipidemia in women: PCOS, menopause, and cardiovascular risk

Brain GPCR targets and circuits controlling food intake

Understanding gene-diet interactions in cardiometabolic health

Interaction effects of genetic variants and dietary intake on the development of metabolic syndrome

ESC/EAS dyslipidemia guidelines: recent updates and evidence base

Korean perspectives on dyslipidemia guidelines: recent update and challenges

Translating guidelines into practice

Non-inflammatory function of dendritic cell in the regulation of obesity-associated heart failure

Hepatic lipotoxicity and fibrotic remodeling in metabolic liver disease

From lipidomics to systems biology: decoding metabolic networks

Atherosclerosis and atherosclerotic cardiovascular disease in Asia: the knowledge gap for the determinants

Air pollution and cardiovascular disease

Microplastics and cardiovascular health: current epidemiological evidence and challenges

Climate change and cardiometabolic disease